Comprehensive pan-cancer analysis of ACSS3 as a biomarker for prognosis and immunotherapy response

被引:0
|
作者
Zhang, Zhanzhan [1 ]
Yan, Hongshan [2 ]
Tong, Hao [1 ]
Guo, Kai [3 ]
Song, Zihan [1 ]
Jin, Qianxu [2 ]
Zhao, Zijun [4 ]
Zhao, Zongmao [1 ]
Shi, Yunpeng [1 ]
机构
[1] Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China
[3] Hebei Med Univ, Affiliated Xing Tai People Hosp, Dept Neurosurg, Xingtai 054000, Hebei, Peoples R China
[4] Capital Med Univ, Sanbo Brain Hosp, Spine Ctr, Beijing 100000, Peoples R China
关键词
ACSS3; Pan-cancer; Glioma; Biomarker; Cell proliferation; Prognosis; Immunotherapy; ACETYL-COA; METABOLISM; ACETATE; TARGET; TUMORS;
D O I
10.1016/j.heliyon.2024.e35231
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: ACSS3 (acyl-CoA synthetase short-chain family member 3) is found in numerous tissues and is linked to tumor cell type development and metastasis. Methods: We conducted a comprehensive pan-cancer analysis of ACSS3. The TCGA (Cancer Genome Atlas), CPTAC (Clinical Proteomic Tumor Analysis Consortium), and HPA databases were used to ascertain the connection between ACSS3 and various types of tumors. Genes in the TCGA database would be identified using cBioPortal queries, and their transcriptome expression would then be verified using GEO data. ACSS3 expression and cellular localization in various tumor tissues of most cancer types were analyzed using single-cell sequencing data from the TISCH database. According to HPA and CPTAC databases, we analyzed and evaluated protein expression levels. Predictive analysis based on precise survival data of ACSS3 expression levels for 26 cancer types predicted using the TCGA database. Furthermore, we investigated the relationship between ACSS3 and immune microenvironments in different tumor tissues using the TIMER and TISCH databases. CellMiner, GDSC, and CTRP data would clarify the relationship between ACSS3 and drug resistance and explore the chemicals that affect ACSS3 expression. The final part of our study explored and validated the role ACSS3 played in glioma proliferation, migration, and invasion. Results: ACSS3 is differentially expressed in various tumors and exhibits early diagnostic value. ACSS3 expression is associated with clinical features, and high ACSS expression anticipates a worse prognosis in multiple tumors and may impact drug sensitivity. The changes in the immunosuppressive microenvironment of gliomas are closely related to the upregulation of ACSS3. Conclusions: ACSS3 is a novel biomarker for forecasting different human cancer prognoses, as it can influence the biological process by modulating the immune microenvironment. ACSS3 is a critical prognostic factor for glioma and is related to its proliferation, migration, and invasion.
引用
收藏
页数:29
相关论文
共 50 条
  • [1] A comprehensive analysis of PANoptosome to prognosis and immunotherapy response in pan-cancer
    Zhuang, Lingling
    Sun, Qiran
    Huang, Shenglan
    Hu, Lanyan
    Chen, Qi
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [2] A comprehensive analysis of PANoptosome to prognosis and immunotherapy response in pan-cancer
    Lingling Zhuang
    Qiran Sun
    Shenglan Huang
    Lanyan Hu
    Qi Chen
    [J]. Scientific Reports, 13
  • [3] Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response
    Ji, Yacong
    Li, Chongyang
    Wan, Sicheng
    Zhang, Kui
    Liu, Yaling
    Shi, Shaomin
    [J]. FUNCTIONAL & INTEGRATIVE GENOMICS, 2024, 24 (02)
  • [4] Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response
    Yacong Ji
    Chongyang Li
    Sicheng Wan
    Kui Zhang
    Yaling Liu
    Shaomin Shi
    [J]. Functional & Integrative Genomics, 2024, 24
  • [5] Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
    Ma, Bo
    Yu, Riyue
    [J]. FRONTIERS IN GENETICS, 2023, 14
  • [6] Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy
    Zhao, Qinfei
    Hu, Weiquan
    Xu, Jing
    Zeng, Shaoying
    Xi, Xuxiang
    Chen, Jing
    Wu, Xiangsheng
    Hu, Suping
    Zhong, Tianyu
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [7] Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response
    Zheng, Hong
    Wang, Minghao
    Zhang, Shiyu
    Hu, Dongxue
    Yang, Qiaoyun
    Chen, Ming
    Zhang, Xia
    Zhang, Yi
    Dai, Jigang
    Liou, Yih-Cherng
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (14): : 4689 - 4708
  • [8] Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy response
    Xu, Shengshan
    Zheng, Youbin
    Ye, Min
    Shen, Tao
    Zhang, Dongxi
    Li, Zumei
    Lu, Zhuming
    [J]. BMC CANCER, 2024, 24 (01)
  • [9] Pan-cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy
    Xu, Hua-Guo
    Chen, Can
    Chen, Lin-Yuan
    Pan, Shiyang
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (03)
  • [10] Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy
    Zhang, Jing
    Wang, Kai
    Hainisayimu, Tuersun
    Li, Hui
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022